Title

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Authors

Authors

R. P. Baughman; K. C. Meyer; I. Nathanson; L. Angel; S. M. Bhorade; K. M. Chan; D. Culver; C. G. Harrod; M. S. Hayney; K. B. Highland; A. H. Limper; H. Patrick; C. Strange;T. Whelan

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abbreviated Journal Title

Chest

Keywords

TUMOR-NECROSIS-FACTOR; PLACEBO-CONTROLLED TRIAL; RABBIT ANTITHYMOCYTE; GLOBULIN; ANTI-TNF THERAPY; PEDIATRIC RENAL-TRANSPLANTATION; RHEUMATOID-ARTHRITIS PATIENTS; CHIMERIC MONOCLONAL-ANTIBODY; ACUTE; CELLULAR REJECTION; PHASE-III TRIAL; CORTICOSTEROID-FREE; IMMUNOSUPPRESSION; Critical Care Medicine; Respiratory System

Abstract

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and inflammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols monitoring to detect manifestations of toxicity and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease

Journal Title

Chest

Volume

142

Issue/Number

5

Publication Date

1-1-2012

Document Type

Article

Language

English

First Page

E1

Last Page

E111

WOS Identifier

WOS:000311010100053

ISSN

0012-3692

Share

COinS